NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM 주식 보고서

시가총액: US$128.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NGM Biopharmaceuticals 관리

관리 기준 확인 2/4

NGM Biopharmaceuticals' CEO는 David Woodhouse, Sep2018 에 임명되었습니다 의 임기는 5.58 년입니다. 총 연간 보상은 $ 5.93M, 10.3% 로 구성됩니다. 10.3% 급여 및 89.7% 보너스(회사 주식 및 옵션 포함). 는 $ 179.29K 가치에 해당하는 회사 주식의 0.14% 직접 소유합니다. 179.29K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 5.6 년입니다.

주요 정보

David Woodhouse

최고 경영자

US$5.9m

총 보상

CEO 급여 비율10.3%
CEO 임기5.6yrs
CEO 소유권0.1%
경영진 평균 재임 기간1.3yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

CEO 보상 분석

David Woodhouse 의 보수는 NGM Biopharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Dec 31 2023n/an/a

-US$142m

Sep 30 2023n/an/a

-US$151m

Jun 30 2023n/an/a

-US$170m

Mar 31 2023n/an/a

-US$178m

Dec 31 2022US$6mUS$610k

-US$163m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$125m

Dec 31 2021US$10mUS$580k

-US$120m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$122m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$5mUS$525k

-US$102m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$490k

-US$43m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$4mUS$413k

-US$493k

보상 대 시장: David 의 총 보상 ($USD 5.93M )은 US 시장( $USD 683.56K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Woodhouse (52 yo)

5.6yrs

테뉴어

US$5,933,500

보상

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

리더십 팀

이름위치테뉴어보상소유권
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Valerie Pierce
Senior VP4.5yrsUS$2.10m0.022%
$ 28.7k
Hsiao Lieu
Chief Medical Officer & Executive VP5.1yrsUS$2.73m0.017%
$ 22.3k
Jean Frederic Viret
Chief Financial Officer1.3yrs데이터 없음데이터 없음
Irene Perlich
VP, Corporate Controller & Principal Accounting Officerless than a year데이터 없음0.011%
$ 13.8k
Daniel Kaplan
Chief Scientific Officer1.3yrs데이터 없음데이터 없음
Mahi Saraf
Director of People & Cultureless than a year데이터 없음데이터 없음
Diana Bockus
Head of Business Development1.8yrs데이터 없음데이터 없음
Arthur Hsu
Senior Director & Head of Biology1.3yrs데이터 없음데이터 없음
Kara Calhoun
Senior Vice President of CMC & Process Developmentless than a year데이터 없음데이터 없음

1.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: NGM 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Grant Heidrich
Special Advisorno data데이터 없음데이터 없음
Arthur Levinson
Special Advisorno data데이터 없음데이터 없음
David Goeddel
Lead Independent Director5.6yrsUS$270.23k19.87%
$ 25.5m
Michael Brown
Chairman of the Scientific Advisory Boardno data데이터 없음데이터 없음
Joseph Goldstein
Member of the Scientific Advisory Boardno data데이터 없음데이터 없음
Roger Perlmutter
Independent Director2.8yrsUS$250.00k0%
$ 0
Shelly Guyer
Independent Director4.3yrsUS$273.09k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Suzanne Hooper
Independent Director5.7yrsUS$265.00k0.0084%
$ 10.8k
Michael Fischbach
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

5.6yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: NGM 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.